Skip to main content
Premium Trial:

Request an Annual Quote

Motorola Bails Out of Deal with Molecular Staging

NEW YORK, May 31 – Motorola has decided to abandon its previously announced plans to exclusively license Molecular Staging’s rolling circle amplification technology for use in its diagnostic nucleic acid bioarrays, a spokeswoman for Molecular Staging said Thursday.

“Motorola does not have an exclusive license to the technology,” a spokeswoman for Molecular Staging said.

The spokeswoman said she did not know what prompted Motorola to cancel the agreement.

A Motorola spokeswoman declined to comment.

In December, Motorola announced that it had reached an agreement to exclusively license Molecular Staging’s technology in exchange for licensing fees and an equity investment in the privately-held company. Motorola also received an option to increase its stake in the company in the future.

It was not immediately clear whether Motorola had also cancelled its plans to invest in Molecular Staging.

RCAT is an amplification method designed to allow users to detect the presence of target molecules on a variety of formats.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.